Homburger advised Windward Bio, a private, clinical-stage biotechnology company, throughout completion of it USD 165 million series B Financing. In connection with the round, BG Partner represented lead investor OrbiMed, Novo Holdings, Blue Owl Capital and
Homburger advised Windward Bio Group — a Swiss-based biotechnology specialist in advanced immunological diseases — in connection with a licensing agreement between the company’s affiliate, LE2025 Therapeutics, and Qyuns Therapeutics Co. for the development
BGPartner has advised OrbiMed and Novo Holdings on Swiss legal matters related to the USD 200 million Series A financing of Windward Bio Group, a Swiss-based clinical-stage drug development company, advised by Homburger. The financing round
